AdaptHealth is selling its approximately $600 million diabetes business to Cardinal Health and exiting certain e-commerce and drop-ship operations to focus on sleep, respiratory and home medical equipment. CEO Suzanne Foster said the diabetes segment lacked expected cross-selling opportunities and would have required significant investment in pharmacy capabilities. The company reported 16% second-quarter revenue growth, though its new West Coast capitated contract faces higher-than-expected costs due to utilisation and hospital-ordering issues. AdaptHealth built 40 new locations to support the contract covering 13 million members. Management highlighted strong growth potential in sleep care, driven by increased referrals and digital tools including home testing and AI-based mask fitting. Capital priorities include organic growth, reducing leverage to 2.5 times and pursuing targeted sleep and respiratory acquisitions.

AdaptHealth faces securities investigation after sharp loss and guidance cut: what AHCO investors need to know. 11 August 2026, 7:36 AM Major securities investigation initiated following Q2 loss and guidance reset. Shareholders of AdaptHealth Corp. (NASDAQ: AHCO) are facing more uncertainty as prominent securities law firm Levi & Korsinsky begins an official investigation into possible securities violations. The inquiry comes on the heels of AdaptHealth's Q2 2026 results, where the company posted a GAAP loss of $0.99 per share - falling far below analyst expectations of roughly $0.15 profit. This surprising gap triggered a sharp drop in AHCO's share price, with losses reaching as much as 26% for investors. Key issue: GAAP loss and reduced guidance raise red flags. AdaptHealth's latest results revealed not only a sizeable quarterly GAAP loss, but also a $144.2 million goodwill impairment charge - a significant hit for any company. Even as adjusted EBITDA landed at $132 million for the quarter, the company simultaneously lowered its full-year 2026 revenue guidance, resetting expectations to $2.85-$2.89 billion and indicating weaker future performance. For investors, the combination of negative earnings, large impairment, and reduced outlook has intensified concerns over management's prior forecasts. | Q2 2026 Metric | Reported Value | | GAAP Earnings Per Share | -$0.99 | | Adjusted EBITDA | $132 million | | Goodwill Impairment Charge | $144.2 million | | Updated 2026 Revenue Guidance | $2.85B-$2.89B | Investigation focus: were revenue and profit targets misleading? The Levi & Korsinsky probe hinges on whether AdaptHealth made materially false or misleading forecasts. Only months after previously issuing its guidance, AHCO revised its 2026 numbers downward - prompting the legal review. If proven, this could potentially open the door for investors who purchased shares before the guidance cut to seek financial recovery, even if those shares have already been sold at a loss. What should AHCO investors do now? * Gather brokerage records, including purchase dates and prices. * Review your AHCO investment history (date, quantity, price paid, and sale, if relevant). * Contact Levi & Korsinsky for a free eligibility evaluation at [email protected] or (212) 363-7500. Participation does not require going to court or paying upfront legal fees; securities claims are typically handled on a contingency basis. Investors should move promptly to ensure their eligibility and potential for recovery. Key takeaway: legal process is underway, and action may preserve recovery options. For AdaptHealth shareholders, the official investigation by a top-50 securities litigation law firm brings a measure of recourse in a turbulent period. If you took losses on AHCO stock, now is the time to act. Gather your records, determine eligibility, and stay tuned - resolution may take time, but early action helps preserve your rights as details emerge. Contact Information: If you have feedback or concerns about the content, please feel free to reach out to Market Chameleon via email at [email protected]. About the Publisher - Marketchameleon.com: Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. Market Chameleon leverage extensive data, models, and analytics to provide valuable insights into these markets. Its primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards. NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com. The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information. Disclosure: This article was generated with the assistance of AI